TNF and Mycobacterium infection: An increased incidence of pulmonary mycobacterial infections and atypical mycobacterial infections has been reported.6 In addition, Winthrop and colleagues7 reported 239 cases of nontuberculous mycobacteria infections in the setting of anti–TNF-α use of which 73 cases were associated with infliximab use.